A Cohort Study for Clinical Evaluation of OmniMax MMF System

Sponsor
Zimmer Biomet (Industry)
Overall Status
Completed
CT.gov ID
NCT03075865
Collaborator
University of Iowa (Other), Medical University of South Carolina (Other), University of California, Davis (Other)
39
3
24
13
0.5

Study Details

Study Description

Brief Summary

OmniMax MMF system was designed as a device with faster application/removal time, less mucosal tissue overgrowth over the plates and screws, better tolerance for placement over prolong periods of time, better patient hygiene and a lower risk for further treatments secondary to root damage from the insertion of the screws, compared to the standard of care for maxillo-mandibular fixation and other hybrid systems. This clinical trial intends to highlight the clinical benefits of the OmniMax MMF system applied to patients undergoing repair of uncomplicated mandibular fracture(s) for whom OmniMax MMF system is used as a single mean for maxillo-mandibular fixation.

Condition or Disease Intervention/Treatment Phase
  • Device: OmniMax MMF system

Detailed Description

The objective of this study is to highlight and evaluate the clinical benefits of OmniMax MMF system applied to patients undergoing repair of uncomplicated mandibular fracture(s). A total of 50 subjects involved in trauma events resulting in uncomplicated mandibular fracture(s) will be enrolled at up to 5 sites from 3 surgical subspecialties: maxillofacial surgery, ENT, and plastic surgery. Subjects considered for participation will receive OmniMax MMF system for maxillo-mandibular fixation for a period of 4 to 8 weeks. Incidence of root damage associated with screw insertion, time for implantation and removal of the device, oral hygiene during the maxillomandibular fixation period, mucosal overgrowth, gingival necrosis, post-operative pain, stability of the occlusion, fracture healing, patient overall satisfaction/compliance with length of treatment, incidence of glove perforation and accidental puncture, will be evaluated in all participants who remain in IMF post-operatively. Adverse Events associated with the use of OmniMax MMF system will also be collected.

Study Design

Study Type:
Observational
Actual Enrollment :
39 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The OmniMax MMF System: A Cohort Study for Clinical Evaluation
Actual Study Start Date :
Jun 28, 2017
Actual Primary Completion Date :
Jan 10, 2019
Actual Study Completion Date :
Jun 28, 2019

Arms and Interventions

Arm Intervention/Treatment
OmniMax MMF

Patients involved in trauma events will receive intermaxillary fixation with OmniMax MMF system for temporary stabilization of mandibular fracture(s) to maintain proper occlusion during surgery and allow for postoperative fracture healing.

Device: OmniMax MMF system
OmniMax MMF system consists of arch bars and screws that work together to achieve temporary fixation of the maxilla and mandible to provide indirect or passive stabilization of fractures and maintenance of occlusion in the oral and maxillofacial region. The arch bars have hooks designed to accommodate either wires or elastic bands for temporary maxillomandibular fixation (MMF) either intraoperative or postoperative.
Other Names:
  • OmniMax
  • Outcome Measures

    Primary Outcome Measures

    1. Root Damage [6 weeks]

      Dental root damage can be caused from insertion of the screws at time of implantation. Some of these events may require further medical or surgical treatment

    Secondary Outcome Measures

    1. Time for Implantation of OmniMax MMF [Operative]

      The OmniMax MMF system, with a better segmentalized design and extended screw slots, allows for fixation of this device using less quantity of screws for fixation (compared to other hybrid systems). This system may impact the efficiency of the medical care by significantly reducing the operative time.

    2. Tissue necrosis and mucosal overgrowth [6 weeks]

      The reduced number of screws needed to fixate a full OmniMax MMF system (8 versus up to 14 in other bone-borne systems) is expected to improve the post-operative gingival tissue health, avoiding soft tissue irritation, overgrowth, compression and necrosis of the gingival area.

    Other Outcome Measures

    1. Patient Satisfaction [6 weeks]

      Less screws for fixation and design of the device to protect the soft tissue is expected to increase the level of patient satisfaction and patient compliance with both, the oral hygiene and the length of fixation period.

    2. Gloves Perforation and Accidental Puncture [Operative]

      Design of OmniMax MMF system is expected to reduce the risk for accidental glove perforation and/or wire puncture during implantation of the device.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Males or females

    • 18 years of age or older

    • Able and willing to sign ICF and medical photography consent

    • Undergoing a surgical procedure to repair uncomplicated mandibular fracture(s) requiring open reduction internal fixation (ORIF) or closed maxillo-mandibular fixation (MMF)

    • Fracture repair done within 10 days after facial trauma

    • Use of OmniMax MMF system as a single mean for IMF (maxillary plate and mandibular plates together with no other device combined, such as Erich bars or IMF screws).

    Exclusion Criteria:
    • General contraindications unfavorable for the use of MMF (psychological disorders, seizures disorders, airway compromise, immune-compromised patients, etc).

    • History of radiation therapy to the head or neck region.

    • Limited blood supply to the area of device application.

    • Insufficient quantity or quality of bone.

    • History of foreign body sensitivity.

    • History of previous use of bisphosphonates (i.e. alendronate, pamidronate, neridronate, olpadronate, ibandronate, risendronate, zolendronate).

    • Clinically active or latent infection.

    • Patients with less than 20 teeth.

    • Deciduous dentition.

    • Patients for whom the use of OmniMax MMF system would not be appropriate in judgment of the surgeon (i.e., excessive overjet or deep overbite).

    • Mandibular fracture pattern that could prevent the use of OmniMax MMF system for adequate reduction and stabilization (i.e., comminuted fractures, dental alveolar fractures).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of California Davis Medical Center Sacramento California United States 95817
    2 University of Iowa Iowa City Iowa United States 52242
    3 College of Dental Medicine Charleston South Carolina United States 29425

    Sponsors and Collaborators

    • Zimmer Biomet
    • University of Iowa
    • Medical University of South Carolina
    • University of California, Davis

    Investigators

    • Study Director: Brian M Hatcher, PhD, Zimmer Biomet CMF & Thoracic

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Zimmer Biomet
    ClinicalTrials.gov Identifier:
    NCT03075865
    Other Study ID Numbers:
    • 1116
    First Posted:
    Mar 9, 2017
    Last Update Posted:
    Jul 19, 2021
    Last Verified:
    Jul 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Zimmer Biomet
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 19, 2021